A new Bristol-Myers Squibb Co. drug helped skin-cancer patients live longer than those who received chemotherapy in a clinical trial, the latest evidence behind a promising new crop of drugs that work by unleashing the body’s immune system against tumors.. It is the first time a late-stage clinical trial has shown that one of a new class of drugs—which block an immune-cell component known as PD-1—improve patient survival compared to a comparator drug. Previous clinical results for the Bristol drug and similar drugs from Merck...
  